<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Itraconazole: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int302-itraconazole.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int302-itraconazole.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int302-itraconazole.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int288-antifungals.htm">Antifungals</a> &gt; <a href="bnf_int300-antifungals-triazole.htm">Antifungals, Triazole</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int301-fluconazole.htm" title="Previous: Fluconazole">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int303-antihistamines.htm" title="Next: Antihistamines">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Itraconazole</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Itraconazole</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int86-alfentanil.htm">Alfentanil</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>alfentanil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1099-aliskiren.htm">Aliskiren</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>aliskiren</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int406-alprazolam.htm">Alprazolam</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>alprazolam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span> <span>itraconazole</span> <span>reduced by</span> <span>antacids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>itraconazole</span> <span>given with</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>bosentan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int496-budesonide.htm">Budesonide</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of inhaled</span> <span>budesonide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>buspirone</span> <span>(reduce dose of <span>buspirone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int993-busulfan.htm">Busulfan</a></td><td><p><span></span> <span>itraconazole</span> <span>inhibits metabolism of</span> <span>busulfan</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td><p><span>negative inotropic effect possibly increased when </span> <span>itraconazole</span> <span>given with</span> <span>calcium-channel blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div></td></tr><tr><td><a href="bnf_int469-calcium-channel-blockers-dihydropyridines.htm">Calcium-channel Blockers (dihydropyridines)</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>dihydropyridines</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>inhibits metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>increased by</span> <span>clarithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>corticosteroids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int502-cyclophosphamide.htm">Cyclophosphamide</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly increases side-effects of</span> <span>cyclophosphamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>dabigatran etexilate</span> <span>—manufacturer of <span>dabigatran etexilate</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>darifenacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>manufacturer of </span> <span>itraconazole</span> <span>advises avoid concomitant use with</span> <span>disopyramide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>dronedarone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>reduced by</span> <span>efavirenz</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int963-eletriptan.htm">Eletriptan</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>eletriptan</span> <span>(risk of toxicity)—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>eplerenone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>everolimus</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int471-felodipine.htm">Felodipine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>inhibits metabolism of</span> <span>felodipine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1119-fesoterodine.htm">Fesoterodine</a></td><td><p><span>manufacturer of fesoterodine advises dose reduction when </span> <span>itraconazole</span> <span>given with</span> <span>fesoterodine</span> <span>—consult <span>fesoterodine</span> product literature</span>  </p></td><td></td></tr><tr><td><a href="bnf_int497-fluticasone.htm">Fluticasone</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of inhaled</span> <span>fluticasone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td><p><span>plasma concentration of both drugs may increase when </span> <span>itraconazole</span> <span>given with</span> <span>fosamprenavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int1170-gefitinib.htm">Gefitinib</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>gefitinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>haloperidol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int743-histamine-h-2-antagonists.htm">Histamine H<sub>2</sub>-antagonists</a></td><td><p><span>absorption of </span> <span>itraconazole</span> <span>reduced by</span> <span>histamine H<sub>2</sub>-antagonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>indinavir</span> <span>(consider reducing dose of <span>indinavir</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>ivabradine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int846-lercanidipine.htm">Lercanidipine</a></td><td><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>lercanidipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int492-methylprednisolone.htm">Methylprednisolone</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>methylprednisolone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1125-micafungin.htm">Micafungin</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>increased by</span> <span>micafungin</span> <span>(consider reducing dose of <span>itraconazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>midazolam</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>inhibits metabolism of</span> <span>mizolastine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>possibly reduced by</span> <span>nevirapine</span> <span>—consider increasing dose of <span>itraconazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1118-nilotinib.htm">Nilotinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>nilotinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>itraconazole</span> <span>reduced by</span> <span>phenytoin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int751-proton-pump-inhibitors.htm">Proton Pump Inhibitors</a></td><td><p><span>absorption of </span> <span>itraconazole</span> <span>reduced by</span> <span>proton pump inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span> <span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int855-repaglinide.htm">Repaglinide</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly enhances hypoglycaemic effect of</span> <span>repaglinide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>itraconazole</span> <span>reduced by</span> <span>rifabutin</span> <span>—manufacturer of <span>itraconazole</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>itraconazole</span> <span>reduced by</span> <span>rifampicin</span> <span>—manufacturer of <span>itraconazole</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>combination of </span> <span>itraconazole</span> <span>with</span> <span>ritonavir</span> <span>may increase plasma concentration of either drug (or both)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>rivaroxaban</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>sildenafil</span> <span>—reduce initial dose of <span>sildenafil</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>itraconazole</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>sirolimus</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1020-solifenacin.htm">Solifenacin</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>solifenacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span>(consider reducing dose of <span>tacrolimus</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>tadalafil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>possibly increased by</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>tolterodine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>vardenafil</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int815-vincristine.htm">Vincristine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>vincristine</span> <span>(increased risk of neurotoxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1181-vinflunine.htm">Vinflunine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>vinflunine</span> <span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1085-vinorelbine.htm">Vinorelbine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>vinorelbine</span> <span>(increased risk of neurotoxicity)</span>  </p></td><td></td></tr></tbody></table><p><strong>Itraconazole</strong> belongs to <strong>Antifungals, Triazole</strong> and will have the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int290-amphotericin.htm">Amphotericin</a></td><td><p><span></span> <span>triazoles</span> <span>possibly antagonise effects of</span> <span>amphotericin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</p></div></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span> <span>triazoles</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>possible increased risk of myopathy when </span> <span>triazoles</span> <span>given with</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td class="cAI"><p><span>increased risk of ergotism when </span> <span>triazoles</span> <span>given with</span> <span>ergotamine and methysergide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int95-fentanyl.htm">Fentanyl</a></td><td class="cAI"><p><span></span> <span>triazoles</span> <span>possibly increase plasma concentration of</span> <span>fentanyl</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>triazoles</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>triazoles</span> <span>possibly increase plasma concentration of</span> <span>quetiapine</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int231-reboxetine.htm">Reboxetine</a></td><td class="cAI"><p><span>avoidance of </span> <span>triazoles</span> <span>advised by manufacturer of</span> <span>reboxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>triazoles</span> <span>possibly increase plasma concentration of</span> <span>rifabutin</span> <span>(increased risk of uveitis—reduce <span>rifabutin</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td><p><span></span> <span>triazoles</span> <span>possibly increase plasma concentration of</span> <span>saquinavir</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Itraconazole</strong> belongs to <strong>Antifungals</strong> but <strong>Antifungals</strong> has no interactions information.</p></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int301-fluconazole.htm">Previous: Fluconazole</a> | <a class="top" href="bnf_int302-itraconazole.htm#">Top</a> | <a accesskey="]" href="bnf_int303-antihistamines.htm">Next: Antihistamines</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>